Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenytoin as an augmentation for SSRI failures: a small controlled study.

B Shapira1, B Nemets, A Trachtenberg

  • 1Schonbaum Depression Department, Herzog Hospital, Jerusalem, Israel.

Journal of Affective Disorders
|July 4, 2006
PubMed
Summary

Phenytoin did not augment antidepressant effects in patients with SSRI failure. This suggests anticonvulsant mood stabilizers may not share lithium

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Family History and Solar Insolation in Bipolar I Disorder.

Acta psychiatrica Scandinavica·2026
Same author

Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial.

Scientific reports·2021
Same author

Corrigendum to "A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder". [J Affect Disord. 15 (2020) 233-238].

Journal of affective disorders·2020
Same author

A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder.

Journal of affective disorders·2020
Same author

International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder.

Psychotherapy and psychosomatics·2019
Same author

Solar insolation in springtime influences age of onset of bipolar I disorder.

Acta psychiatrica Scandinavica·2017

Area of Science:

  • Psychiatry
  • Pharmacology
  • Neuroscience

Background:

  • Lithium augmentation is established for antidepressant non-responders.
  • Phenytoin exhibits antimanic, antidepressant, and prophylactic properties in affective disorders.

Purpose of the Study:

  • To investigate phenytoin's potential to augment antidepressant effects in patients with selective serotonin reuptake inhibitor (SSRI) failure.

Main Methods:

  • A study involving 25 patients was conducted.
  • Data from 20 patients were analyzed for comparisons between phenytoin and placebo.

Main Results:

  • No significant antidepressant augmentation effect was observed with phenytoin.

Conclusions:

Related Experiment Videos

  • Phenytoin augmentation was ineffective in SSRI-resistant depression.
  • The mood-stabilizing properties of anticonvulsants like phenytoin may not extend to augmenting antidepressant efficacy.
  • Lithium's augmentation effect might be distinct from that of anticonvulsant mood stabilizers.